Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval

Biomerica, Inc. BMRA stock is surging with a session volume of 139.2 million as per data from Benzinga Pro.

The company announced its Fortel Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP).

The Fortel PSA Screening Test is a user-friendly diagnostic tool that provides accurate results in just 10 minutes using a simple finger-prick blood sample.

By measuring elevated PSA levels, a recognized early marker of prostate disease, the test can enable early detection of prostate cancer and other prostate-related conditions.

The Fortel PSA test has demonstrated outstanding performance in rigorous evaluations:

• A study reported 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods.
• Research conducted at the Faculty of Medicine, Ain Shams University in Egypt, further validated the test’s effectiveness, achieving 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy.

Prostate cancer is the second most common cancer among men worldwide. Roughly 1.4 million new cases were diagnosed and 375,000 deaths were reported globally in 2020.

On Wednesday, Biomerica reported second-quarter 2025 earnings. Biomerica reported net sales of $1.64 million, a 5% increase from the $1.57 million recorded in the same quarter of the previous year. This growth in sales, driven by sustained demand from both new and existing customers.

The company reported an operating loss of $990,000. That’s down 39% from $1.6 million. It also suffered a net loss of $950,000, down 37% from $1.5 million.

Price Action: Biomerica stock is up 209% at $1.08 at last check Thursday.

Read Next:

• Toyota Subsidiary Agrees To $1.6B Settlement Over Emission Data Fraud

Image: Shutterstock